首页> 中文期刊> 《疑难病杂志》 >重组人脑钠肽治疗扩张型心肌病顽固性心力衰竭的临床研究

重组人脑钠肽治疗扩张型心肌病顽固性心力衰竭的临床研究

         

摘要

目的探讨重组人脑钠肽(rhBNP)治疗扩张型心肌病顽固性心力衰竭的临床疗效。方法50例扩张型心肌病顽固性心力衰竭患者随机分为重组人脑钠肽治疗组和米力农对照组各25例。2组均给予常规抗心力衰竭药物治疗,治疗组给予注射用rh BNP,对照组给予米力农静脉滴注。观察2组治疗后的临床疗效,心率、平均动脉压、尿量、心功能及血浆BNP水平变化。结果治疗后1周,治疗组总有效率为883.0%,明显高于对照组的64.0%,差异有统计学意义( P <0.05)。治疗后24 h,2组心率明显下降( P <0.05),平均动脉压明显降低( P <0.05),尿量明显增加( P <0.01),且治疗组心率下降、尿量增多均优于对照组( P <0.05)。2组治疗后24 h血浆BNP水平较基线值明显降低( P <0.01),治疗后1周治疗组的左心室射血分数(LVEF)较治疗前提高( P <0.05);血浆BNP显著降低,治疗组治疗后LVEF改善和血浆BNP降低均明显好于对照组( P <0.01或P <0.05)。结论 rhBNP治疗扩张型心肌病顽固性心力衰竭患者疗效显著,可明显改善患者的心力衰竭症状。%Objective To explore the clinical effects of recombinant human brain natriuretic peptide (rh-BNP) in thetreatment of decompensated heart failure in patients with dilated cardiomyopathy .Methods A total of 50 patients with dilatedcardiomyopathy who suffered from decompensated heart failure were randomly divided into rh -BNP treatment group and milrinonecontrol group, 25 cases in each group.Both groups were treated with conventional drugs against heart failure .Treatmentgroup was injected rh-BNP while control group given intravenous drip of milrinone .Heart rates, mean arterial pressures, urinevolume, heart functions, plasma BNP and clinical effects of 2 groups before and after treatment were observed .Results Comparedwith before treatment in one week , the total effective rate of treatment group(88.0%)was notably higher than those ofcontrol group(64.0%),the difference was statistically significant ( P <0.05).After the treament, heart rates of treatmentgroupsconspicuously decreased in 24 hours, Treatment group were significantly lower heart rate ( P <0.05), mean arterialpressure was significantly lower ( P <0.05), significantly increased urine volume ( P <0.01).whereas urine volume distinctlyincreased.Besides, the left ventricular ejection fraction (LVEF) in one week and plasma BNP in 24 hours of 2 groupswere obviously improved after treatment , whereas the increased LVEF and the decreased plasma BNP in treatment group weresignificantly notable than those in control group ( P <0.01, P <0.05).Conclusion rh-BNP, being capable of amelioratingheart failure symptoms of patients evidently , has marked therapeutic effects in the treatment of decompensated heart failure inpatients with dilated cardiomyopathy .

著录项

  • 来源
    《疑难病杂志》 |2014年第10期|995-997|共3页
  • 作者单位

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

    214400 江阴市人民医院/东南大学医学院附属江阴医院心内科;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

    重组人脑钠肽; 扩张型心肌病; 心力衰竭,顽固性; 临床疗效;

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号